Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells

Maintenance chemotherapy in the management of epithelial ovarian cancer

(2015) Maurie Markman   CANCER AND METASTASIS REVIEWS

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

(2015) Avi Ashkenazi   JOURNAL OF CLINICAL INVESTIGATION

Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation

(2015) Ching-Yi Liu et al.   Oncotarget

Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model

(2015) Daniel Benten et al.   NEOPLASIA

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

(2014) P. Schoffski et al.   ANNALS OF ONCOLOGY

“Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?

(2014) Alison Davis et al.   GYNECOLOGIC ONCOLOGY

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System

(2014) W. Ruprecht Wiedemeyer et al.   Frontiers in Oncology

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) J. A. Ledermann et al.   ANNALS OF ONCOLOGY

An international assessment of ovarian cancer incidence and mortality

(2013) Kimberly A. Lowe et al.   GYNECOLOGIC ONCOLOGY

Flow cytometry based assays for the measurement of apoptosis-associated mitochondrial membrane depolarisation and cytochrome c release

(2013) Melinda E. Christensen et al.   METHODS

Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models

(2013) S. Xu et al.   MOLECULAR CANCER THERAPEUTICS

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

(2013) T-V Do et al.   ONCOGENE

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

Optimal first-line treatment in ovarian cancer

(2012) F. A. Raja et al.   ANNALS OF ONCOLOGY

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

(2012) A. M. Petrich et al.   CLINICAL CANCER RESEARCH

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

p21WAF1 and tumourigenesis

(2012) Noel A. Warfel et al.   CURRENT OPINION IN ONCOLOGY

Danusertib, an aurora kinase inhibitor

(2012) Hielke J Meulenbeld et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors

(2011) Lifang Xie et al.   BIOCHEMICAL PHARMACOLOGY

Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells

(2011) Piyush B. Gupta et al.   CELL

Cell death by autophagy: facts and apparent artefacts

(2011) D Denton et al.   CELL DEATH AND DIFFERENTIATION

Cdc2: a monopotent or pluripotent CDK?

(2011) X. Hu et al.   CELL PROLIFERATION

The dual role of autophagy in cancer

(2011) Eeva-Liisa Eskelinen   CURRENT OPINION IN PHARMACOLOGY

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Aurora kinase inhibitors as anti-cancer therapy

(2010) Warren Lok et al.   ANTI-CANCER DRUGS

Apoptosis promotes early tumorigenesis

(2010) D Tang et al.   ONCOGENE

Epithelial–Mesenchymal Transition: From Molecular Mechanisms, Redox Regulation to Implications in Human Health and Disease

(2009) Stefania Cannito et al.   ANTIOXIDANTS & REDOX SIGNALING

Ovarian cancer

(2009) Bryan T Hennessy et al.   LANCET

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

Autophagy in the Pathogenesis of Disease

(2008) Beth Levine et al.   CELL

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis

(2008) Jing Yang et al.   DEVELOPMENTAL CELL

Apoptosis: controlled demolition at the cellular level

(2007) Rebecca C. Taylor et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY